Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Scientists have identified how specific genetic changes function in cells to influence disease risk and other human health ...

The panel ensures compatibility with our previous autosomal Family Finder tests plus all the autosomal transfers we ...

The mixed DNA sample found at Nancy Guthrie's house is complicating the search for her, after she was taken from her Arizona ...

In India, rare diseases are not so rare. It is estimated that around 70 million Indians live with one of more than 7,000 rare diseases, many of which are genetic […] ...

BioVenic is dedicated to advancing the advancement of veterinary molecular diagnostics through its comprehensive ...

The global single nucleotide polymorphism (SNP) genotyping market size was valued at USD 7.24 billion in 2025 and is predicted to hit around USD 19.48 billion by 2034, rising at a 11.7% CAGR, a study ...

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

A structural aberration (SA) with secondary implications (SASIs) involving a cancer susceptibility gene is identified on chromosome microarray in approximately 0.6% tests performed on index cases.

Study of 99 pediatric patients found clinically significant CNVs in 30% of cases, supporting CMA as a first-tier test for developmental delay and ID. Clinically significant CNVs were identified in 30% ...